EP1575614A1 - Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom - Google Patents

Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom

Info

Publication number
EP1575614A1
EP1575614A1 EP02808241A EP02808241A EP1575614A1 EP 1575614 A1 EP1575614 A1 EP 1575614A1 EP 02808241 A EP02808241 A EP 02808241A EP 02808241 A EP02808241 A EP 02808241A EP 1575614 A1 EP1575614 A1 EP 1575614A1
Authority
EP
European Patent Office
Prior art keywords
orf
ppvo
polynucleotide
seq
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02808241A
Other languages
German (de)
French (fr)
Inventor
Olaf c/o Bayer Corp. WEBER
Sonja Maria Friederichs
Angela Siegling
Tobias Schlapp
Andrew Allan Mercer
Stephen Bruce Fleming
Hans-Dieter Volk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to EP10178276A priority Critical patent/EP2351769A3/en
Priority to EP13175420.2A priority patent/EP2647645B1/en
Publication of EP1575614A1 publication Critical patent/EP1575614A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • PPVO NZ2 is another Parapoxvirus strain that exhibits immuno stimulatory effects when administered in inactivated form to mammals.
  • compositions which contain fewer (and may not contain any) inactive components (i.e., polynucleotides and proteins of PPVO) in addition to the active components.
  • the invention also relates to purified and isolated polynucleotide which encode for the same amino acid sequence as the active fragments of the PPVO genome of the previous paragraph and to polynucleotides of at least 15 or 30 or 100 nucleotides binding under stringent conditions to the above mentioned active fragments of the PPVO genome or its complementary sequence.
  • the invention also relates to the use of a recombinant viruses comprising a Vaccinia lister genome and at least one heterologous gene for gene therapy.
  • the invention also relates to
  • the extent of CD8+ -T cell activation was measured by determining the extent of EL-2 release from T cells by specific sandwich ELISA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions.

Description

Recombinant proteins of Parapoxyirus ovis and pharmaceutical compositions therefrom
Field of the invention
The present invention relates to polynucleotides and recombinant proteins of Parapoxvirus ovis (PPVO) and their use, alone or in combination with other substances, for the manufacture of pharmaceutical compositions.
Background of the invention
It is known that latent and chronically persistent viral infections can be activated or reactivated by immuno suppression, or conversely that the immune system suppresses acute diseases which may be caused by a latent virus (for example a latent herpes virus infection recurs as a result of immunosuppression in the form of lip vesicles in cases of stress or the administration of cortisone). It is also known that chronically persistent latent viral infections can only be treated with difficulty or not at all using conventional low^-molecular-weight antiviral substances.
It was demonstrated that class I restricted cytotoxic T cells were capable of inhibiting hepatocellular HBN gene expression in HBN-transgenic mice, and that this process was caused by TΝF-α and IFΝ-γ.
- It is also known that in the case of chronically persistent viral infections a super- infection with another virus can produce antiviral effects against the chronically persistent virus. The dependence of this effect on interferons such as IFΝ-γ, as well as other cytokines and chemokines, such as TΝF-α, which are secreted by T cells, natural killer cells and macrophages, has been demonstrated. BAYPAMUN®, a pharmaceutical product for inducing "paraspecific immunity", i.e., a pharmaceutical product for inducing the unspecific immune system, is used therapeutically, metaphylactically and prophylactically for the treatment of animals in need. BAYPAMUN® is manufactured from chemically inactivated PPVO strain D1701 (see German Patent DE3504940). The inactivated PPVO induces in animals non-specific protection against infections with the most diverse types of pathogens. It is assumed that this protection is mediated via various mechanisms in the body's own defense system. These mechanisms include the induction of interferons, the activation of natural killer cells, the induction of "colony-stimulating activity" (CSA) and the stimulation of lymphocyte proliferation. Earlier investigations of the mechanism of action demonstrated the stimulation of interleukin-2 and interferon-α.
The processes for the production of the above-mentioned pharmaceutical compositions are based on the replication of the virus in cultures of suitable host cells. ■ ■
One aspect of the invention relates to the use of particle-like structures comprising recombinant proteins of the invention. These particle-like structures can be, e.g., fusion proteins, protein-coated particles or virus-like particles.
Methods to produce fusion proteins, protein-coated particles or virus-like particles comprising recombinant proteins of the invention are well known to persons skilled in the art: Casal (Biotechnol. Genet. Eng. Rev. 2001, 18: 73-87) describes the use of baculovirus expression systems for the generation of virus-like particles. Ellis (Curr. Opin. Biotechnol. 1996, 7(6): 646-52) presents methods to produce virus-like particles and the application of suitable adjuvants. Roy (Intervirology 1996, 39(1-2):
62-71) presents genetically engineered particulate virus-like structures and their use as vaccine delivery systems. Methods to produce fusion proteins are also well known to the person skilled in the art (Gaudin et al, Gen. Virol. 1995, 76: 1541:56; • Hughson, Curr. Biol. 1995, 5(3): 365-74; Uhlen et al., Curr. Opin. Biotechnol. 1992, 3(4): 363-369). Known to the person skilled in the art is also the preparation of protein-coated micro- and nanospheres (Axshady, Biomaterials 1993, 14(1): 5-15). Proteins can be attached to biodegradable microspheres (Cleland, Pharm Biotechnol. 1997, 10: 1-43) or attached to other polymer microsheres (Hanes et al, Pharm. Biotechnol. 1995, 6:389-412) such as, e.g., polysaccharides (Janes et al., Adv. Drug Deliv. Rev. 2001, 47(1): 83-97).
PPVO NZ2 is another Parapoxvirus strain that exhibits immuno stimulatory effects when administered in inactivated form to mammals.
The closest prior art describes the construction of an expression library representing about 95 % of the PPVO NZ2 genome using the Vaccina lister virus to create recombinant viruses comprising the complete Vaccina lister genome and various fragments of the PPVO genome (Mercer et al. 1997, Virology, 229: 193-200). For the construction of the library, 16 PPVO DNA fragments with an average size of 11,4 kb were inserted into the Vaccinia lister genome. Each fragment was mapped relative to the PPVO restriction endonuclease maps but was otherwise uncharacterized (Fig. 1).
It was found that a major portion of the PPVO genes were expressed in cells infected by the recombinant virus. The authors also showed that the entirety of all PPVO proteins expressed by some of the recombinant viruses of the expression library was able to provide protection against challenge with virulent PPVO. Expression of PPVO genes of the individual recombinant viruses has been demonstrated by irrununofluorescence and immune precipitation (Mercer et al. .1997, Virology, 229:
193-200).
To identify components of PPVO responsible for the vaccinating activity of PPVO, the Vaccinia listerl PPVO NZ2 expression library was applied.
Based on the above background it was desirable to develop PPVO based pharma-
' ceutical compositions with antiviral and anti-tumor efficacy as well as with efficacy in paraimmunization and other desirable therapeutic effects. It was also desirable to obtain a pharmaceutical composition that exerts its full therapeutic effect while showing fewer side effects. It was furthermore desirable to fnd methods to produce PPVO based pharmaceutical compositions in large quantities and in economically advantageous manners.
These desirable effects have been achieved by the systematic use of selected recombinant proteins of PPVO alone or in combination with other recombinant proteins 'from PPVO for the preparation of pharmaceutical compositions for the treatment of objects in need.
Summary of the invention
The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to fragments of said polynucleotides of at least 15 or 30 or 100 base pairs in length. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins of at least 5 or 10 or 30 amino acids, and to the use of recombinant proteins or fragments for the preparation of pharmaceutical compositions.
"Fragments" of a polynucleotide, within the meaning of the invention, shall be understood as polynucleotides that have the same nucleotide sequence as contiguous parts of the full length (the original) polynucleotide.
"Active fragments", within the meaning of the invention, shall be those fragments of the PPVO genome the expression products of which have demonstrated to be pharmacologically active according to the invention, when inserted into the Vaccina lister genome and expressed in a suitable host.
Whereas the use of the complete PPVO virus for the manufacture of vaccines against PPVO challenge has been described, the present invention relates to the use of polynucleotides coding for the PPVO viral genome and selected fragments of the PPVO viral genome and of selected PPVO expression products, alone or in combination with others, for the preparation of improved pharmaceutical compositions for the treatment of various diseases.
The systematic use of selected genomic fragments of PPVO and their recombinant expression products makes it possible to produce pharmaceutical compositions which contain fewer (and may not contain any) inactive components (i.e., polynucleotides and proteins of PPVO) in addition to the active components.
These pharmaceutical compositions which contain less, or do not contain any additional inactive components are generally preferred by doctors and patients compared to the less well defined biological preparations of inactivated virus material. Furthermore, the possibility of producing the recombinant product in fermentation processes allows an economically advantageous mode of production. It is well known to persons skilled in the art that an economically advantageous mode of production can be achieved, e.g., by using rapidly growing production organisms (host organisms) which might also place low demands on the culture medium employed. Microorganisms which can advantageously be used as hosts for the production of recombinant proteins include, e.g., but are not limited to, Escherichia coli, Bacillus spec, Corynebacterium spec, Streptomyces spec, as well as yeasts, e.g., Saccha- romyces cerevisiae, Candida spec.', Pichia spec, Hanselula spec, and filamentous fungi, e.g., Aspergillus spec, Penicillium spec, and other suitable microorganisms.
Recombinant proteins of the invention can also be produced from cell lines expressing the proteins of interest. These cell lines can be recombinant mammalian cell lines, recombinant insect cell lines (e.g., using the baculovirus transfection system) or other suitahle expression systems. Transfection can be achieved by various techniques known to the skilled person, one of which is the use or recombinant viruses such as the. Vaccinia viruslP?VO recombinants (WOVs) described in the examples. Description of the invention
The invention relates to fragments of the PPVO genome of at least 15 or 30 or 100 • base pairs in length, and recombinant proteins expressed therefrom and to the use of said fragments and recombinant proteins for the preparation of pharmaceutical compositions. The invention also relates to individual genes (ORFs) of PPVO and their expression products, and their use, alone or in combination with others, for the preparation of pharmaceutical compositions.
A protein, within the meaning of the invention, is any polypeptide of at least five amino acids. A recombinant protein, within the meaning of the invention, is any protein that is expressed in a cell, to which the coding polynucleotide was introduced using recombinant DNA technology.
A polynucleotide, within the meaning of the invention, is meant, to comprise, poly- rc'bonucleotides and/or polyrfe-SOxyrtbonucleotides.
Pharmaceutical compositions of the invention can be used as immunotherapeutic or immunoprophylactic agents for the treatment of infectious and non-infectious immuno- deficiencies. They can also be used for the treatment of tumor diseases, cancer, viral infections and diseases associated therewith, such as, e.g., hepatitis, papillomatosis, herpes virus infections, liver fibrosis, for the prevention or prophylaxis of infectious diseases after stress (e.g. operations), for the prevention and prophylaxis of infectious diseases by administration prior to operations or procedures (e.g. preceding i plan- tations of artificial limbs or dental procedures), for the prophylactic and metaphylactic treatment of non-viral infections, for the healing of wounds, and in particular for accelerating wound-healing processes and for promoting the healing of poorly healing or non-healing wounds (e.g. Ulcus cruris), for diseases such as multiple sclerosis, warts and other skin neoplasms, for allergic diseases, for preventing the onset of systemic allergies and for topical allergies and for improving well-being, e.g. in old age, for autoimmune diseases, chronic inflammatory diseases, such as, e.g., Crohn's disease, COPD and asthma. It is an object of the invention to use of polynucleotides and recombinant proteins of PPVO for the production of pharmaceutical compositions for the treatment of the above mentioned conditions and diseases in humans and animals.
The viral strains of the invention are PPVO NZ2 and homologues, such as D1701,
NZ7, NZ10 and orf-11 strains. It is also possible to use polynucleotides and recombinant proteins of the progeny of these strains obtained by passaging and/or adaptation using specific cells, such as e.g. WI-38, -VIRC-5 or Vero cells.
We have found that the identified recombinant proteins are effective for the treatment of viral diseases, cancer and other diseases or conditions in which a Thl type immune response is of benefit. The results obtained also imply that PPVO gene products or parts thereof protect hepatitis virus-expressing hepatocytes (e.g. hepatitis B virus, HBV, or hepatitis C virus, HCV) from immune attack through HBV or HCV specific cytotoxic CD 8+ T cells circulating in the blood because T cells will not leave the blood stream if their specific antigen is not presented by liver sinus endothelial cells (LSEC, that anatomically separate hepatocytes from T cells passing the liver with the blood). Therefore, we expect to have a recombinant protein that is derived from the ORFs 120-R3 (base pairs 122616 - 136025 Bp, recombinant virus WOV82) that is able to down-modulate or prevent side effects such as necro- in lammatory liver disease when immunostimulants, e.g. cytokines or any others including the proteins described above administered to e.g. hepatitis patients.
Considering the knowledge about the influence of a Thl type immune induction in conditions and diseases such as latent and or chronic viral infections, proliferative diseases such as cancer and the capability of recombinant proteins. that contain gene products of PPVO or parts thereof- to induce a Thl immune response or a local ' immune response selectively, we claim the use of polynucleotides and recombinant polypeptides of PPVO and recombinant proteins that contain gene products of PPVO or parts thereof for the manufacture of pharmaceutical compositions for use in humans and animals. The recombinant proteins are made from products or parts thereof of the following open "reading frames (ORFs) of PPVO NZ2: 64r-96r (recombinants VVOV 285 and WOV 330 as well as VVOV 243 and VVOV 283), 18r-57 (recombinants VVOV 97, VVOV 96 and VVOV 245), 4r-14r (recombinant WOV 215). The recombinant protein may also be made from gene products or parts thereof of ORFs 120-R3 (recombinant VVOV 82). The proteins may be prepared and used in any combination.
Recombinant proteins of PPVO within the meaning of the invention shall be understood as proteins that derive from PPVO and are expressed in homologous or heterologous systems other than the systems in which PPVO is naturally produced.
• Examples for recombinant proteins of PPVO are proteins of PPVO which are expressed using Vaccinia virus vectors and fibroblasts as host cells or baculovirus vectors and insect cells as host cells. Recombinant proteins, within the meaning of the invention, could also be produced in bacterial cells (e.g., Escherichia coli, Bacillus spec, Streptomyces spec.) or in yeast (e.g. Saccharomyces cerevisiae,
Candida spec, Pichia pastoris, Hansenula spec) systems, fri these cases, polynucleotides of the PPVO genome would typically be brought into the respective host genome so that PPVO genes are expressed by the host. Recombinant proteins of PPVO could also be expressed by the object in need in the sense of a gene therapy.
Recombinant proteins, within the meaning of the invention, could also be recombinant virus particles that contain PPVO derived proteins. Recombinant proteins, within the meaning of the invention, could also be in form of viral-like particles that are formed or assembled from PPVO derived proteins. Recombinant proteins, within the meaning of the invention, could also be chimeric proteins that contain PPVO gene products.
' In a preferred embodiment of the invention the recombinant proteins are attached to particle-like structures or be part of particle-like structures. In another preferred embodiment of the invention the recombinant proteins are attached to, or part of, fusion proteins.
In another preferred embodiment of the invention the recombinant proteins are attached to, or part of, protein-coated particles.
In another preferred embodiment of the invention the recombinant proteins are attached to, or part of, virus-like particles.
Particle-like structures, such as particle-like fusion proteins, protein-coated particles or- virus-like particles can be phagocytosed and processed by monocytes or macrophages. The process of phagocytosis enhances the efficacy of recombinant proteins of the invention in uses within the meaning of the invention.
A particle- like structure, within the meaning of the invention, is particulate matter in particle-like form of which the average particle size and other characteristics are suitable for medical application. Preferred particle-like structures are, e.g., fusion proteins, protein-coated particles, or virus-like particles.
Immunomodulating activity is defined as local or systemic suppression and/or stimulation and/or induction of any Th-1 or Th-2 type cytokine response or of any effector function of these cytokines, (e.g. cytolytic or antiviral activity or humoral response) or the modulation of MHC cross-presentation. Immunomodulating activity could also be the induction of apoptosis in antigen presenting cells or recruiting of antigen presenting cells.
Nucleotides and recombinant proteins of the invention can be administered at the same time or sequentially, administered with other agents and drugs, e.g. with drugs that treat the disease or are supportive, e.g. in the case of cancer therapy with antineoplastic or other anti-cancer agents or/and anti-coagulants or vitamins, pain relief and others. The nucleotides and recombinant proteins can be administered systemically (e.g., intravenously, subcutaneously, intramuscularly, intracutaneously, intraperitoneally), locally (e.g., into a tumor) or orally (per os). The recombinant proteins or products thereof should be formulated appropriately, e.g. in a non-pyrogenic solution or suspension for i.v. use or in capsules for implantation or in capsules for per os use. Pharmaceutical compositions of the invention can be administered, e.g., oral, nasal, anal, vaginal etc., as well as parenteral administration. Pharmaceutical compositions of .the invention can be in the form of suspensions, solutions, syrups, elixirs or appropriate formulations in polymers as well as liposomes.
Recombinant proteins of the invention can also be prepared with suitable recombinant cell lines and other cell lines. Alternatively, non-recombinant cell lines, such as WI-3'8, MRC-5, Vero cells could be infected with recombinant viruses that carry the recombinant genes using viral vectors such as, but not limited to, the
Vaccina virus (e.g., Vaccina lister). In addition, other suitable viruses can be used in combination with other suitable cells (e.g., using Vaccinia virus vectors and fibroblasts as host cells or baculovirus vectors and insect cells as host cells). It is advantageous to cultivate the recombinant cell cultures in high-cell-density fermen- tations to achieve favorable productivity and a good overall process performance.
The invention relates to purified and isolated polynucleotides with the sequence of SEQ ED 01. The invention also relates to purified and isolated polynucleotides of at least 15 or 30 or 100 nucleotides which bind under stringent conditions to the poly- nucleotide of SEQ ED 01 or its complementary sequences.
Stringent conditions, within' the meaning of the invention are 65°C in a ■buffer ' containing 1 mM EDTA, 0.5 M NaHPO4 (pH 7.2), 7 % (w/v) SDS.
The invention also relates to purified and isolated' olynucleotides which comprise the polynucleotide sequence of SEQ ED 01 or polynucleotide sequences encoding the same amino acid sequence and fragments of at least 15 or 30 or .100 nucleotides thereof. The invention also relates to recombinant proteins of five and more amino acids encoded by these polynucleotides.
The invention also relates to purified and isolated polynucleotides which show at least 99 %, 95 % or 90 % or 80% sequence homology to the polynucleotides of the previous paragraph.
Homology of biological sequences, within the meaning of the invention, shall be understood as the homology between two biological sequences as calculated by the algorithm of Needleman and Wunsch. (1970. J. Mol. Biol. 48: 443-453) using the BLOSUM62 substitution matrix (Henikoff and Henikoff 1992. Proc. Natl. Acad. Sci. USA 89:10915-10919) for proteins and penalties of +4 and -3 for identical and non- identical bases, respectively, when comparing polynucleotide sequences. For com- parison of protein sequences the gap creation penalty and the gap extension penalty are 8 and 2, respectively. For comparison of polynucleotide sequences the gap creation penalty and the gap extension penalty are 20 and 3, respectively.
The invention also relates to purified and isolated polynucleotides which are active fragments of the PPVO genome, with a sequence selected from a group of sequences consisting of nucleotides 122616-136025 of SEQ TD 01 (PPVO insert of WON 82), 31003-46845 of SEQ ED 01 (PPVO insert of VVOV 96), 24056-33789 of SEQ TD 01 (PPVO insert of WOV 97), 10264-20003 of SEQ ED 01 (PPVO insert of WOV 215), 82324-92502 of SEQ ED .01 (PPVO insert of VVOV 243), 47952-66263 of SEQ ED 01 (PPVO insert of WOV 245), 89400-103483. of SEQ ED 01 (PPVO insert of WOV 283), 74804-88576 of SEQ TD 01 (PPVO insert of VVOV 285), and 102490-108393 of SEQ ED 01 (PPVO insert of VVOV 330).
The invention also relates to purified and isolated polynucleotide which encode for the same amino acid sequence as the active fragments of the PPVO genome of the previous paragraph and to polynucleotides of at least 15 or 30 or 100 nucleotides binding under stringent conditions to the above mentioned active fragments of the PPVO genome or its complementary sequence.
The invention also relates to polynucleotides with 99 %, 95 %, or 90 %, or 80 % sequence homology to sequences consisting of nucleotides 122616-136025 of SEQ
TD 01 (PPVO insert of VVOV 82), 31003-46845 of SEQ TD 01 (PPVO insert of VVOV 96), 24056-33789 of SEQ ED 01 (PPVO insert of VVOV 97), 10264-20003 of SEQ ED 01 (PPVO insert of WOV 215), 82324-92502 of SEQ ED 01 (PPVO insert of VVOV 243), 47952-66263 of SEQ ED 01 (PPVO insert of WOV 245), 89400-103483 of SEQ ED 01 (PPVO insert of VVOV 283), 74804-88576 of SEQ ED
01 (PPVO insert of VVOV 285), and 102490-108393 of SEQ ED 01 (PPVO insert of VVOV 330) or the respective complementary sequences.
The invention also relates to purified and isolated polynucleotide, with a sequence of nucleotides 3 to 539 (ORF LI), 781 to 449 (ORF L2r), 1933 to 1664 (ORF L3r),
3269 to 2790 (ORF L4r), 2799 to 3851 (ORF L5), 2962 to 3753 (ORF L6), 3784 to 3122 (ORF L7r), 4341 to 4129 (ORF L8r), 4904 to 4428 (ORF lar), 6517 to 4970 (ORF lr), 8042 to 6684 (ORF 2r), 9989 to 8070 (ORF 3r), 11195 to 10062 ORF 4r), 11493 to 11227 (ORF 5r), 11802 to 12038 (ORF 6), 12358 to 12080. (ORF 7r), 13980 to 12364 (ORF 8r), 14826 to 14053 (ORF 9ar), 15080 to 15394 (ORF 10),
16838 to 15423 (ORF l lr), 19021 to 16847 (ORF 12r), 19704 to 19156 (ORF 13r), 20314 to 19736 (ORF 14r), 20401 to 22101 (ORF 15), 22125 to 22940 (ORF 6), 23003 to 23866 .(ORF 17), 26908 to 23873 (ORF 18r), 26926 to 27213 (ORF 19), 27626 to 27216 (ORF 20r), 29754 to 27616 (ORF 21r), 32217 to 29800 (ORF 22r), 33380 to 32418 (ORF 23r), 33602 to 33393 (ORF 24r), 34466 to 33612 (ORF 25r),
34735 to 34502 (ORF 26r), 35905 to 34739 (ORF 27r), 37194 to 35905 (ORF 28r), 37200 to 39248 (ORF 29), 41037 to 39229 (ORF 30r), 41374 to 42066 (ORF 31), '42336 to 41731 (ORF 32r), 42407 to 41997 (ORF 33r), 42410 to 43765 (ORF 34), 43770 to 43958 (ORF 35), 43980 to 44534 (ORF 36), 45727 to 44537 (ORF 37r), 45760 to 46557 (ORF 38), 46567 to 47568 (ORF 39), 47572 to 48303 (ORF 40),
48352 to 48621 (ORF 41), 49887 to 48634 (ORF 42r), 49917 to 50693 (ORF 43), 50719 to 51102 (ORF 44), 51059 to 51511 (ORF 44a), 51584 to 52591 (ORF 45), 52509 to 53066 (ORF 46), 53523 to 53023 (ORF 47r), 53607 to 57473 (ORF 48), 58070 to 57528 (ORF 49r), 57700 to 58662 (ORF 50), 59674 to 58673 (ORF 51r), ' 62089 to 59678 (ORF 52r), 62198 to 62881 (ORF' 53), 62909 to 63862 (ORF 55), 63858 to 64271 (ORF 56), 64309 to 66831 (ORF 57), 67266 to 66799 (ORF 58r), 67803 to 67273 (ORF 58ar), 67915 to 68607 (ORF 59), 68624 to 70984 (ORF 60), 70994 to 72898 (ORF 61), 72938 to 73507 (ORF 62), 73540 to 74211 (ORF 63), 76120 to 74207 (ORF 64r), 76749 to 76186 (ORF 65r), 77698 to 76799 (ORF 66r), 79343 to 77709 (ORF 67r), 79816 to 79367 (ORF 68r), 80529 to 79858 (ORF 69r), 80774 to 80529 (ORF 70r), 82815 to 80788 (ORF 71r), 83835 to 82834 (ORF 72r), 83874 to 85583 (ORF 73), 85535 to 84402 (ORF'74r), 88096 to 85574 (ORF 75r), 87759 to 88667 (ORF 76), 88920 to 88642 (ORF 77r), 91652 to 88938 (ORF 78r), 91667 to 92674 (ORF 79), 93466 to 92681 (ORF 80r), 93761 to 93486 (ORF 81r), 94060 to 93788 (ORF 82r), 94238 to 94080 (ORF 83r), 94508 to 94242 (ORF 84r), 95571 to 94498 (ORF 85r), 96187 to 95600 (ORF 86r), 96202 to 97665 (ORF 87), 97915 to 97643 (ORF 88r), 98251 to 99537 (ORF 89), 99537 to 99974 (ORF 90), 100001 to 101140 (ORF 91), 101168 to 104650 (ORF 92), 106354 to 104795 (ORF 93r), 107947 to 106400 (ORF 94r), 108256 to 107990 ORF 95r), 108719 to 108300 (ORF 96r), 109679 to 108738 (ORF 97r), 109861 to 109682 (ORF 98r), 110830 to 10033 (ORF 99r), 110208 to 110417 (ORF 100), 110469 to 110651 (ORF 100a), 110915 to lli397 (ORF 101), 111419. to 111913 (ORF 102), 111949'to 112485 (ORF 103), 112593 to 113450 (ORF 104), 113323 to 112967 ORF 105r), 113526 to 114152 (ORF 106), 114199 to 115236 (ORF 107), 11535.3 to 115787 (ORF 108), 115859 o 116551 (ORF 109), 116729 to 117523 (ORF 110), 117572 to 117114 (ORF lll'r), 117423 to 118085 (ORF 12), 118968 to 118375 (ORF 114r), 118508 to 119119 (ORF 115), 119588 to 120202 (ORF 116), 120314 to 21231 (ORF 117), 121380 to 123920 (ORF 118), 121288 to 122256 (ORF 119), 122350 to 123924 (ORF 120), 123962 to 125566 (ORF 121), 125193 to 124591 (ORF 122r), 125689 to 123935 (ORF 123r), 123839 to 123297 ORF 123ar), 125652 to 126170 (ORF 124), 126121 to 125699 (ORF 125r), 126279 to 127769 (ORF 126), 127851 to 128408 (ORF 127), 128520 to 130076 (ORF 128), 130105 to 131700 (ORF 129), 131790 to 133283 (ORF 130), 133246 to 133920 (ORF 131), 133972 to 134370 (ORF 132), 134418 to 134693 (ORF 133a), 134402 to 134992 (ORF RI), 134853 to 134419 (ORF R2r), 135628 to 135897 (ORF R3), 136780 to 137112 ORF R4), and 137558 ' to 1370.22 (ORF R5r) of SEQ ED 01, which encode for the identified open reading frames (ORFs) listed in Table 7. ORFs of this paragraph of which the start position is a larger number than the stop position are coded by the complementary sequence of SEQ ED 01. The names of these ORFs end with the letter "r". The invention also relates to the complementary sequences of the sequences of this paragraph.
The invention also relates to polynucleotides which encode for the same amino acid sequence as encoded by the identified ORFs of the previous paragraph. The invention also relates to polynucleotides of at least 15, 30 or 100 nucleotides binding under • stringent conditions to the identified ORFs. The invention also relates to polynucleotides which show at least 99 %, 95 % or 90 % or 80 % sequence homology to the sequences of the previous paragraph or which are functional variants a sequence of the previous paragraph.
A. functional variant of a gene, within the meaning of the invention, shall be defined as a gene which is at least 99 %, or 95 %, or 90 %, or 80 % homologous to the first gene and which has a similar biological function as the first gene. A functional variant of a gene can also- be a second gene encoding the same amino acid sequence as does the first gene (or as does a functional variant thereof), employing the degeneration of the genetic code. A functional variant of a gene can also be a polynucleotide comprising the same sequence as has said gene, however said poly- nucleotide being shorter (i.e., by means of deletions of one or several nucleotides at one or both ends of the polynucleotide) or said polynucleotide having additional nucleotides at one or both ends of the identical part of the polynucleotide.
A functional variant of a protein, within the meaning of the invention, shall be defined as another protein which is at least 99 %, or 95 %, or 90 %, or 80 % homologous to the first protein and which has a similar biological function as has the original protein.
The invention also relates to recombinant proteins encoded by nucleotides of the invention and parts and fragments of said proteins which are at least 5 or 7 or 10 or
30 amino acids long.
The invention also relates to recombinant proteins encoded by nucleotides of the invention and parts and fragments of said proteins which are at least 5 or 7 or 10 of 30 amino acids long, said recombinant proteins being attached to a carrier protein or to another carrier. Attaching a protein to a carrier protein can improve or strengthen the immune response to said protein, thereby enhancing the therapeutic or prophylactic effect of administering said protein to a subject.
The invention also relates to vectors containing polynucleotides of the invention and cells containing these vectors or polynucleotides of the invention.
The invention also relates to the use of recombinant proteins and polynucleotides of the invention, alone or in combination with at least one other recombinant protein or polynucleotide of the invention for the manufacture of pharmaceutical compositions.
Combinations of recombinant proteins (or polynucleotides) according to the invention, comprise
• combinations of at least two recombinant proteins encoded by SEQ ED 01 (or combinations of at least two fragments of a polynucleotide of SEQ ED 01),
• combinations of at least two recombinant proteins encoded by the same active fragment of the PPVO genome, i.e., two or more recombinant proteins encoded by the same WOV of Table 3, Table 4, Table 5, and Table 6 (or combinations of at least two fragments of the same active fragment (VVOV) of the PPVO genome),
• combinations of at least two recombinant proteins, encoded by at least two distinct active fragments of the PPVO genome, i.e., from distinct VVOVs of
Table 3, Table 4, Table 5, and Table 6 (or combinations of at least two fragments of at least two distinct active fragments (VVOVs) of the PPVO genome), or
• combinations of at least two distinct recombinant proteins encoded by ORFs of Table 7 (or combinations of at least two polynucleotides with the sequence of any of the ORFs listed in Table 7).
The invention also relates to the use of recombinant viruses comprising the Vaccina lister genome and selected fragments of the PPVO genome for the manufacture of pharmaceutical compositions.
The invention also relates to the use of recombinant proteins and polynucleotides of the invention for the manufacture of pharmaceutical compositions for the treatment of virus related diseases, viral infections, non- viral infections, proliferative diseases, inflammatory diseases, allergic diseases, and autoimmune diseases.
Viral infections, within the meaning of the invention, shell be understood as diseases associated with viral infections of the human or animal body, such as hepatitis, papiUomatosis, herpes virus infections, liver fibrosis, HTV infections, AIDS, and influenza.
Non-viral infections, within the meaning of the invention, shell be understood as diseases associated with non-viral infections of the human or animal body, such as infections with mycobacteria, mycoplasma, amoebia, and plasmodia. Proliferative diseases, within the meaning of the invention, shell be understood as diseases associated with proliferative disorders, such as cancer, leukemia, warts, tumor diseases, and other skin neoplasms.
Inflammatory diseases, within the meaning of the invention, shell be understood as diseases associated with acute or chronic inflammatory conditions, such as inflammation of the skin or organs, Crohn's disease, COPD, Asthma, but also conditions related to the healing of wounds, e.g. Ulcus cruris., and others.
Allergic diseases, within the meaning of the invention, shell be understood as comprising both systemic and topical allergies.
Autoimmune diseases within the meaning of the invention, shell be understood as comprising systemic lupus erythematosus, Sjogren's syndrome, Hashimoto's thyroiditis, rheumatoid arthritis, and juvenile diabetes mellitus. and other autoimmune diseases. " .
The invention also relates to the use of recombinant viruses comprising a Vaccinia lister genome and fragments of a PPVO genome for the manufacture of pharma- ' ceutial compositions.
The invention also relates to the use of recombinant viruses comprising a Vaccinia lister genome and at least one heterologous gene to express at least one heterologous . gene in a subject, e.g., for prophylactic and/or therapeutic purposes.
The invention also relates to the use of a recombinant viruses comprising a Vaccinia lister genome and at least one heterologous gene for gene therapy.
"Gene therapy", within the meaning of the invention, shall be understood as the act of administering to a subject polynucleotides (and, if necessary, suitable adjuvants or suitable carriers) for the purpose of obtaining a prophylactic or therapeutic effect in said subject. Typically, the polynucleotides administered are expressed in the subject and the expressed gene products exert a prophylactic or therapeutic effect.
The invention also relates to
(a) a particle-like structure comprising a recombinant polypeptide encoded by an open reading frame (ORF) of the polynucleotide of SEQ ED NO: 1 or . functional variants of said polypeptides,
(b) the use of a particle-like structure of (a) for the preparation of a medicament,
(c) the use of a particle-like structure of (a) for the preparation of a medicament for the treatment of virus, related diseases, viral infections, non-viral infections, proliferative diseases, inflammatory diseases, allergic diseases, and/or autoimmune diseases,
(d) pharmaceutical compositions comprising a particle-like structure of (a), and to
(e) pharmaceutical compositions comprising a particle-like structure of (a) for the treatment of virus related diseases, viral infections, non-viral infections, proliferative diseases, inflammatory diseases, allergic diseases, and/or autoimmune diseases.
Brief description of the figures
Figure 1 shows the genomic locations of the DNA fragments constituting ' the insertion library. The position of each DNA fragment is shown against the Kpnl map of PPVO NZ2 (Mercer et al. 1997, Virology, 229: 193-200). Examples
Example 1 : Determination of the integrated PPVO Fragments in the active WO Vs.
DΝA preparation from Vaccinia lister/PWO recombinants was performed as follows:
BK-KL 3 A cells were grown to confluency in 175 cm2 flasks (Becton Dickson Lab ware, Heidelberg, Germany). Cells were infected with a recombinant Vaccina foter/PPVO virus (VVOV) of Mercer et al. (1997, Virology, 229: 193-200) at a MOI
(multiplicity of infection) of 0.01-0.32 and incubated at 37°C until 100 % CPE (cytopathic effect) had been reached. The infected cells were frozen at -80°C, thawed and processed as follows, with modification to the RΝA extraction method of Vilcek et al. (1994, J. Clin. Microbiol. 32: 2225-2231). Using 2 ml PLG Heavy Eppendorf tubes (Eppendorf, Hamburg, Germany) 0.5 ml aliquots of cellular suspension were incubated with 100 μg Proteinase K (Roche Molecular Biochemicals, Mannheim, Germany) and 50 μl SDS (Sigma- Aldrich, Chemie GmbH, Taufkirchen, Germany) at 56°C for 25 min.. 0.5 ml Roti®-Phenol/Chloroform (Carl Roth GmbH, Karlsruhe, Germany) was added and the tubes were inverted for several times. After centrifugation at 12000 x g for 10 min, the upper phase was transferred into a fresh tube and two volumes of ethanol (Merck Eurolab GmbH, Darmstadt, Germany) and 1/10 volume of sodium acetate (Sigma- Aldrich, Chemie GmbH, Taufkirchen, Germany) was added. The reagents were mixed several times and stored at -80°C for 3 h. The tubes were centrifuged at 14000 x g for 30 min, the supernatant was decanted and the pellet was air-dried for 5-10 min. Finally the DΝA pellet was resuspended in 30 μl nuclease free water and stored at -20°C until used.
DΝA concentration was measured spectrophotometrically on a BioPhotometer 6131 (Eppendorf, Hamburg, Germany) at 260/280 nm. nm. The DΝA yield of different sample preparations spanned from 100 ng/ml up to 1 μg/ml. Polymerase chain reaction (PCR) of terminal flanking regions of the integrated fragments in the Vaccinia fater PPVO recombinants was performed as follows:
Three different PCR amplification systems were used for amplifying the terminal flanking regions. Each reaction mixture of 50 μl contained 100 ng - 1 μg re- suspended DNA and primers (Table 1)) were added in a final concentration of 300 IJM. Amplifications were carried out on a Mastercycler® gradient (Eppendorf, Hamburg, Germany).
The 3-prime flanking region of recombinant VVOV 285 had been analyzed using 2 x.
Ready-Mix™ PCR Master Mix (1.5 mM MgCl ) (AB Gene, Hamburg, Germany). 1 μl BSA (MBI Fermentas GmbH, St. Leon-Rot, Germany) was added to each reaction. Denaturation was performed at 94°C for 3 min, followed by 30 cycles (94°C for 30 s, 58.7°C - 65.3°C for 30 s, 72°C for 1 min) and 72°C for 5 min. '
' The 5-prime flanking region of the PPVO insert of recombinant WOV 285, the 3- pri e flanking region of VVOV 97, and both terminal flanking regions of WOV 215, WOV 243, WOV 245 were amplified using PfuTurbo® DNA Polymerase (Stratagene, Amsterdam, Netherlands). The reactions were setup with 2.5 U of enzyme, 1.5 mM MgCl2 and 200 μM of each dNTP. Denaturation was performed at 94°C for 3 min, followed by 30 cycles (94°C for 30 s,'58.7°C - 65.3°C for 30 s, 72°C for 1 min) and 72°C for 5 min.
The amplification of the 5-prime flanking region of WOV 97 and VVOV 82, the 3- prime flanking region of VVOV 96 and WOV 283 were performed with
Platinium® Pfx DNA Polymerase (Life Technologies GmbH, Karlsruhe, Germany). A reaction of 50 μl contained 1.25 U polymerase, 1-1.5 mM MgCl2 and 300 μM of each dNTP. Additional use of PCRx Enhancer Solution was necessary for amplification of the 5-prime flanking regions of VVOV 96 (lx concentrated) and the ' 3-prime flanking regions of WOV 82 (2x concentrated). Denaturation was performed at 94°G for 2 min, followed by 30 cycles (94°C for 15 s, 54.6°C - 60.7°C for 30 s, 68°C for 1-2 min) and 68°C for 5-7 min.
18 μl of each amplification product was analyzed by agarose gel electrophoresis on 1.5-2 % SeaKem LE agarose (Biozym, Hessisch Oldendorf, Germany). After staining in a ethidium bromide solution for 20 min the DNN fragments were visualized on an UN transilluminator UNT-20 M/W (Herolab, Wieslpch, Germany).
The sequence of the amplified DΝA-fragments were determined by standard sequencing procedures and compared to the published Vaccinia lister thyrnidine kinase-sequence and the genome sequence of PPVO ΝZ2 to determine exactly the integrated PPVO NZ2 sequences.
Table 1
PCR-primers, amplification and sequencing of the terminal flanldng regions of the integrated fragments in the Vaccinia listerlPFYO NZ2 recombinants
to t
Table 1 (continued)
t
Example 2: Induction of interferon gamma and tumor necrosis factor alpha by PPVO gene products
The 16 recombinants were tested of their ability to induce tumor necrosis factor alpha (TNF-α) and interferon gamma (EFN-γ) in whole blood cultures.
Whole blood cultures containing blood and RPMI medium (Life Technologies GmbH, Karlsruhe, Germany) in the ratio of 1 :5 were stimulated with the recombinant viruses. A pure Vaccinia lister and a whole PPVO preparation served as controls. All preparations were used at a final dilution of 1:10. The stimulation for the EFN-γ determination was done together with ConcanavalinA (SIGMA, St. Louis, MO), because the virus alone does not induce EFN-γ. Then the cells were incubated for 24 h (TNF-α) and or 72 h (EFN-γ). The cytokine concentration was then determined in the cell culture supernatants by TNF-α or EFN-γ specific ELISA. These time points were found to be optimal when the experimental conditions were determined using whole
PPVO as a control.
It was possible to identify 5 active recombinant viruses (VVOV 96, VVOV 97, WOV 243, WOV 285, and VVOV 330) that induced both TNF-α and EFN-γ secretion and, thus, could mimic the effect of the whole PPVO. The results are depicted in Table 2.
Table 2
TNF-α was determined after 24 h stimulation of blood cells with the recombinant virus or the controls, respectively. IFN-γ was determined after 72 h stimulation of blood cells with the recombinant virus or the controls. Stimulation was performed in the presence of the mitogen ConA. The relative induction in percent of the Vaccinia virus control is shown. Therefore, values greater than 100 % are due to the activity of the PPVO fragments. Active PPVO fragments are in bold. The data represent mean values of three different blood donors.
Table 3
The recombinant Vaccinia lister! PPVO viruses that induce both interferon gamma and TNF-α expression are listed in column 1, the corresponding PPVO sequence in column 2 and all open reading frames (ORFs) that are completely or partially contained in the recombinant are depicted in column 3.
Example 3: Local immunomodulation . by PPVO gene products in liver sinus endothelial cells (LSEC) .
We have established a new cell-based assay system that allows testing of hepato- protective properties of recombinant PPVO proteins expressed in different systems (e.g., Vaccinia virus). This assay system uses primary murine liver cells, which play the central role in deciding whether immunity or tolerance is induced in the liver, the
LSEC. The unique ability of LSEC to present exogenous antigens to CD 8+ T cells on MHC class I molecules allows immune surveillance of hepatocytes as viral antigens released by infected hepatocytes are likely to be taken by LSEC and presented to cells . of the immune system. The new assay allows to measure the ability of LSEC to interact antigen-specifically with CD8+ T cells, that are responsible for tissue destruction in necroinflammatory hepatitis. Pure populations of LSEC are isolated from murine liver by a stepwise procedure of portal-vein perfusion with collagenase A (0.05 %), mechanical dispersion and further enzymatic digestion in a rotatory waterbath for 40 min at 37°C (245 rpm), gradient centrifugation (metrizamide 1.089g/cm3) and centrifugal elutriation using a Beckman Avanti J25I centrifuge equipped with a JE-6B rotor and a standard elutriation chamber. LSEC cell populations isolated by this method are typically around 95- 99 % pure as measured by uptake of endothelial cell specific substrate (acetylated low density lipoprotein). LSEC were seeded onto collagen type I coated 24 well tissue culture plates at a density of 100.000 cells per well and were further cultured in Dulbecco's modified Eagle Medium supplemented with 5 % fetal calf serum
(specially tested not to interfere with the assay system) and 2 % glutamine. Three days after isolation, when LSEC gained a postmitotic and quiescient state, we tested for the ability of LSEC to present soluble ovalbumin to (ovalbumin-specific) CD8+ T cells. LSEC were incubated with 1 μM of ovalbumin for three hours (antigen dose and time were previously shown to be optimal for testing of substances suspected to influence antigen-presentation), washed and incubated with a CD8+ T cell hybridoma (200.000 cells/well) that recognizes the peptide SHNFEKL. S-TNFEKL is recognized in a H2b context and directly binds on the MHC-I molecules. Therefore, it has not to be processed by the cell. This allows to differentiate between, accessory functions of LSEC (such as MHC-I expression) and antigen-processing function.
The extent of CD8+ -T cell activation was measured by determining the extent of EL-2 release from T cells by specific sandwich ELISA.
Using Vaccinia virus expressed recombinant proteins derived from PPVO we have been able to attribute hepatoprotective activity to individual clones. To be able to compare different clones directly with respect to their ability to influence cross- presentation by LSEC, we used equal amounts of "infectious units".
We found that LSEC cross-present exogenous ovalbumin very efficiently on MHC class I molecules (kb) to CD8+ T cells. To our surprise we found if LSEC were incubated with several recombinant PPVO proteins we observed subsequently a potent downregulation of cross-presentation by more than 60 % compared to the mock-treated control that includes all but the active ingredient. Several regions within the genome of PPVO have immunregulatory properties. Especially the region termed 82 (43 % reduction) which is located at the 3" end of the genome appears to be responsible for the overall effect of PPVO on cross-presentation by LSEC. Further regions (WOV 215, VVOV 212, WOV 247 and WOV 86) bear further immunregulatory potential, although to a lesser degree (around 30 % reduction in cross-presentation). It further appears that genes coding for proteins that down- regulate cross-presentation are arranged in clusters. It is of interest to note that we identified two gene clusters coding for proteins that improved cross-presentation (VVOV 330, VVOV 283, VVOV 285, VVOV 97, and WOV 96). However, for unknown reasons the downregulatory effect of the proteins' mentioned above is dominant in the activity of PPVO on cross-presentation.
Our results strongly suggest that PPVO contains a mixture of different proteins that in a complementary way work to eliminate hepatocytes from hepatitis B virus while conserving hepatic integrity and avoiding long lasting damage secondary to hepatic fibrosis. As PPVO contains a gene with high homology to the anti-inflammatory agent EL-IO (located in the 5-prime region of the genome) we wondered whether the potent downregulatory effect of the clone 82 was due to expression of ovine EL-10. This assumes that there is cross-reactivity between murine and ovine EL-10 at the level of receptor recognition. We have been unable to demonstrate involvement of ovine EL-10 on the immunoregulatory potential of PPVO. Recombinant murine IL-10 did not show any influence on cross-presentation through LSEC and several monoclonal antibodies to murine and human EL-10 did not influence PPVO mediated downregulation of cross-presentation. We conclude that the immunoregulatory component of PPVO is probably not EL-10 but a new, so far not identified mediator. The data for the MHC-I cross-presentation - down-modulating recombinant virus are depicted in Table 4, those for the MHC-I cross-presentation - stimulating recombinant viruses in Table 5. Table 4
The recombinant Vaccinia lister/ PPVO virus that down-modulates the MHC-I cross presentation is designated in column 1, the corresponding PPVO sequence in column 2 and all open reading frames (ORFs) that are completely or partially contained in the recombinant are depicted in column 3.
Active recombinant PPVO NZ2 Sequence PPVO NZ2 ORFs PPVO Vaccinia virus [Bp] that is contained in that are contained in the recombinant the recombinant
VVOV 82 122616 - 136025 120 - R3
Table 5
The recombinant Vaccinia lister/ PPVO viruses that stimulate the MHC-I cross presentation are designated in column 1, the corresponding PPVO sequence in column 2 and all open reading frames (ORFs) that are completely or partially contained in the recombinant are depicted in column 3.
Example 4: Determination of the immuno stimulatory activity of the Vaccinia lister / PPVO recombinants in the Aujeszky mouse model
We also tested the activity of recombinant Vaccinia listerfPTVO NZ2 -viruses in the Aujeszky mouse model, a lethal challenge model of acute Suid Herpesvirus 1 disease for determining the activity of various immunostimulators (e.g. Baypamun®, CpG oligonucleotides).
a) Conditions employed for the mice
The NMRI mice (outbreed strain HdsWin:NMRI; female; weight: 18-20 g; obtained via Harlan/Winkelmann, Borchen, Germany) were kept in auto- clavable polycarbonate crates lined with sawdust in an S2 isolation stall at 20- 22°C (atmospheric humidity: 50-60 %) and subjected to an artificial day/night rhythm (illumination from 6:30 h to 18:30 h and darkness from 18:30 h to
6:30 h). They had free access to feed and water.
b) Challenge model
Groups of mice consisting of 10 mice per group were used for the tests. All of the animals in one group were given the same test substance.
After the mice were supplied they were kept in the animal stall for 2-3 days. Then the Vaccinia lister -/PPVO NZ2 recombinants were diluted with PBS (Life Technologies GmbH, Karlsruhe, Germany) to a titer equivalent of approx. 10 TC-D5o/ml and thermally inactivated (twice for one hour at 58°C). Of these solutions 0.2 ml was administered per mouse intraperi- toneally.
24 hours after the treatment the mice were infected with the pseudorabies virus of the
Hannover H2 strain by intraperitoneal administration. For this purpose the virus was diluted in PBS to a test titer of approx. 104 TCED5o/ml and 0.2 ml of this suspension was administered.
As a negative control one group of mice was treated with PBS and then infected. The mice in this group died 3-8 days after infection. A large proportion of the mice treated the Vaccinia lister/PTVO NZ2 recombinants VVOV 215, WOV 245, VVOV 285 or VVOV 330 survived infection with the pseudorabies virus. 10 days after the infection with the virus the test was ended.
The level of induced immunostimulation was' determined by comparing the number of dead mice in the PBS control group with the number of dead mice in the test groups and was quantified by the efficacy index (El). This index indicates the percentage proportion of mice protected against the lethal effects of the Aujeszky virus infection through immune stimulation by the substance to be tested. It is calculated by means of the following formula:
EI = (b-α)/b x l00,
where b is the percentage proportion of the dead mice in the control group and a the percentage proportion of the dead mice in the test group.
A chi-square test was used for the statistical evaluation. This test reveals the minimum activity indices indicating a significant difference between the mortality rate of those mice treated with the test substance and those treated with PBS. Activity indices of > 60 % are significant where at least 5 of the mice used in tests with n=6 mice per group in the PBS control group and at least 7 of the mice used in tests with n=10 in the PBS control group do not survive the infection with the Aujeszky virus.
Altogether 3 separate tests were carried out in each case. The testing of Vaccinia b'ster/PPVO NZ2 recombinants in the Aujeszky mouse model shows the following: Surprisingly, after the treatment of the mice with the Vaccinia UsterfP'PVO NZ2 recombinants VVOV 215, VVOV 245, VVOV 285 or WOV 330 the average activity indices of higher than 60 % demonstrated i munostimulation. By contrast all of the other Vaccinia listej-fPTVO NZ2 recombinants were ineffective. The data is summarized in Table 6.
Table 6
The recombinant Vaccinia lister/ PPVO viruses that protected mice from herpesvirus induced death are designated in column 1, the corresponding PPVO sequence in column 2 and all open reading frames (ORFs) that are completely or partially contained in the recombinant are depicted in column 3.
Table 7
Sequences of the Parapox ovis open reading frames. ORFs the names of which end with "r" are encoded on the complementary DNA strand. Base pair positions in the "from" and "to" column are relative to SEQ ED 01.

Claims

Claims
1. Purified and isolated polynucleotide with the sequence of SEQ D 01 or its complementary sequence and fragments and functional variants thereof.
2. Purified and isolated polynucleotide with a sequence selected from a group of sequences consisting of nucleotides number 122616 to 136025 of SEQ ED 01 (PPVO insert of WOV 82), 31003 to 46845 of SEQ ED 01 (PPVO insert of VVOV 96), 24056 to 33789 of SEQ TD 01 (PPVO insert of VVOV 97), 10264 to 20003 of SEQ TD 01 (PPVO insert of VVOV 215), 82324 to 92502 of SEQ TD 01 (PPVO insert of VVOV 243),' 47952 to 66263 of SEQ ED 01 (PPVO insert of WOV 245), 89400 to 103483 of SEQ ED 01 (PPVO insert of WOV 283), 74804 to 88576 of SEQ ED 01 (PPVO insert of VVOV 285), and 102490 to 108393 of SEQ ED 01 (PPVO insert of VVOV 330) or their complementary sequences and functional variants thereof.
3. Purified and isolated polynucleotide with a sequence selected from a group of sequences consisting of nucleotides 3 to 539 (ORF LI), 781 to 449 (ORF L2r), 3269 to 2790 (ORF L4r), 2799 to 3851 (ORF L5), 2962 to 3753 (ORF L6), 3784 to 3122 (ORF L7r), 4341 to 4129 (ORF L8r), 8042 to 6684 (ORF
2r), 9989 to 8070 (ORF 3r), 11493 to 11227 (ORF 5r), 11802 to 12038 (ORF 6), 12358 to 12080 (ORF 7r), 13980 to 12364 (ORF 8r), 14826 to 14053 (ORF 9ar), 15080 to 15394 (ORF 10), 16838 to 15423 (ORF llr), 19021 to 16847 (ORF 12r), 20314 to 19736 (ORF 14r), 20401 to 22101 (ORF 15), 22125 to 2940 (ORF 16), 23003 to 23866 (ORF 17), 26908 to 23873 (ORF
18r), 26926 to 27213 (ORF 19), 27626 to 27216 (ORF 20r), 29754 to 27616 (ORF 21r), 32217 to 29800 (ORF 22r), 33380 to 32418 (ORF 23r), 33602 to 33393 (ORF 24r), 34466 to 33612 (ORF 25r), 34735 to 34502 (ORF 26r), 35905 to 34739 (ORF 27r), 37194 to 35905 (ORF 28r), 37200 to 39248 (ORF 29), 41037 to 39229 (ORF 30r), 41374 to 42066 (ORF 31), 42336 to 41731
(ORF 32r), 42407 to 41997 (ORF 33r), 42410 to 43765 (ORF 34), 43770 to 43958 (ORF 35), 43980 to 44534 (ORF 36), 45727 to 44537 (ORF 37r),
' 45760 to 46557 (ORF 38), 46567 to 47568 (ORF 39), 47572 to 48303 (ORF
40), 48352 to 48621 (ORF 41), 49887 to 48634 (ORF 42r), 49917 to 50693
(ORF 43), 50719 to 51102 (ORF 44), 51059 to 51511 (ORF 44a), 51584 to 52591 (ORF 5), 52509 to 53066 (ORF 46), 53523 to 53023 (ORF 47r), 53607 to 57473 (ORF 48), 58070 to 57528 (ORF 49r), 57700 to 58662 (ORF 50), 59674 to 58673 (ORF 51r), 63858 to 64271 (ORF 56), 64309 to 66831 (ORF 57), 67266 to 66799 (ORF 58r), 67803 to 67273 (ORF 58ar), 67915 to 68607 (ORF 59), 68624 to 70984 (ORF 60), 70994 to 72898 (ORF 61), 72938 to 73507 (ORF 62), 73540 to 74211 (ORF 63), 76120 to 74207 (ORF 64r),
76749 to 76186 (ORF 65r), 77698 to 76799 (ORF 66r), 79343 to 77709
(ORF 67r), 79816 to 79367 (ORF 68r), 80529 to 79858 (ORF 69r), 80774 to
• 80529 (ORF 70r), 82815 to 80788 (ORF 71r), 83835 to 82834 (ORF 72r),
83874 to 85583 (ORF 73), 85535 to 84402 (ORF 74r), 88096 to 85574 (ORF 75r), 87759 to 88667 (ORF 76), 91652 to 88938 (ORF 78r), 91667 to 92674 (ORF 79), 93466 to 92681 ORF 80r), 93761 to 93486 (ORF 81r), 94060 to 93788 (ORF 82r), 94238 to 94080 (ORF 83r), 94508 to 94242 (ORF 84r), 95571 to 94498 (ORF 85r), 96187 to 95600 (ORF 86r), 96202 to 97665 (ORF 87), 97915 to 97643 (ORF 88r), 98251 to 99537 (ORF 89), 99537 to 99974 (ORF 90),100001 to 101140 (ORF 91), 101168 to 104650 (ORF 92), 109679 to 108738 (ORF 97r), 109861 to 109682 (ORF 98r), 110830 to 110033 (ORF 99r), 110208 to 110417 (ORF 100), 110469 to 110651 (ORF 100a), 110915 to.111397 (ORF 101), 111419 to 111913 (ORF 102), 111949 to 112485 (ORF 103), 112593 to 113450 (ORF 104), 113323 to 112967 (ORF 105r), 113526 to 114152 (ORF 106), 114199 to 115236 (ORF 107), 115353 to 115787 (ORF 108), 115859 to 116551 (ORF 109), 117572 to 117114 (ORF lllr), 117423 to 118085 (ORF 112), 118968 to 118375 (ORF 114r), 118508 to 119119 (ORF 115), 119588 to 120202 (ORF 116), 120314 to 121231 (ORF 117), 121380 to 123920 (ORF 118), 121288 to 122256 (ORF 119), 122350 to 123924 (ORF 120), 123962 to 125566 (ORF 121), 125193 to 124591 (ORF 122r), 125689 to 123935 (ORF 123r), 123839 to 123297 (ORF 123ar), 125652 to 126170 (ORF 124), 126121'to 125699 (ORF 125r), 126279 to 127769 (ORF 126), 127851 to 128408 (ORF 127), 128520 to 130076 ' (ORF 128), 136780 to 137112 (ORF R4), andl37558 to 137022 (ORF R5r) of SEQ ED 01 or their complementary sequence and functional variants thereof.
4. Recombinant proteins of encoded by a polynucleotide of any of claims 1, 2 or 3, or functional variants or fragments of more than five amino acids thereof.
5. Vector comprising a polynucleotide of claims 1, 2 or 3.
6. Cells containing vectors of claim 5 or a polynucleotide of claims 1, 2 or 3.
7. Use of a recombinant' protein encoded by a polynucleotide selected from a group of polynucleotides consisting of
(a) a polynucleotide of claim 1 ,
(b) a polynucleotide of claim 2, and
(c) a polynucleotide with a sequence selected from a group of sequences consisting of nucleotides 3 to 539 (ORF LI), 781 to 449 (ORF L2r), 1933 to 1664 (ORF L3r), 3269 to 2790 (ORF L4r), 2799 to 3851 (ORF L5), 2962 to 3753 (ORF L6), 3784 to 3122 (ORF L7r), 4341 to 4129 (ORF L8r), 4904 to 4428 (ORF lar), 6517 to 4970 (ORF lr), 8042 to - 6684 (ORF 2r), 9989 to 8070 (ORF 3r), 11195 to 10062 ORF 4r),
11493 to 11227 (ORF 5r), 11802 to 12038 (ORF 6), 12358 to 12080 (ORF 7r), 13980 to 12364 (ORF 8r), 14826 to 14053 (ORF 9ar), 15080 to 15394 (ORF 10), 16838 to 15423 (ORF llr), 19021 to 16847 (ORF 12r), 19704 to 19156 (ORF 13r), 20314 to 19736 (ORF 14r), 20401 to 22101 (ORF 15), 22125 to 22940 (ORF 6), 23003 to 23866 (ORF 17),
26908 to 23873 (ORF 18r), 26926 to 27213 (ORF 19), 27626 to 27216 (ORF 20r), 29754 to 27616 (ORF 21r), 32217 to 29800 (ORF 22r), 33380 to 32418 (ORF 23r), 33602 to 33393 (ORF 24r), 34466 to 33612 (ORF 25r), 34735 to 34502 (ORE 26r), 35905 to 34739 (ORF 27r), 37194 to 35905 (ORF 28r), 37200 to 39248 (ORF 29), 41037 to 39229 (ORF 30r), 41374 to 42066 (ORF 31), 42336 to 41731 (ORF 32r),
42407 to 41997 (ORF 33r), 42410 to 43765 (ORF 34), 43770 to 43958 (ORF 35), 43980 to 44534 (ORF 36), 45727 to 44537 (ORF 37r), 45760 to 46557 (ORF 38), 46567 to 47568 (ORF 39), 47572 to 48303 (ORF 40), 48352 to 48621 (ORF 41), 49887 to 48634 (ORF 42r), 49917 to 50693 (ORF 43), 50719 to 51102 (ORF- 44), 51059 to 51511 (ORF
44a), 51584 to 52591 (ORF 45), 52509 to 53066 (ORF 46), 53523 to 53023 (ORF 47r), 53607 to 57473 (ORF 48), 58070 to 57528 (ORF 49r), 57700 to 58662 (ORF 50), 59674 to 58673 (ORF 51r), 62089 to 59678 (ORF 52r), 62198 to 62881 (ORF 53), 62909 to 63862 (ORF 55), 63858 to 64271 (ORF 56), 64309 to 66831 (ORF 57), 67266 to 66799
(ORF 58r), 67803 to 67273 (ORF 58ar), 67915 to 68607 (ORF 59), 68624 to 70984 (ORF 60), 70994 to 72898 (ORF 61), 72938 to 73507 (ORF 62), 73540 to 74211 (ORF 63), 76120 to 74207 (ORF 64r), 76749 to 76186 (ORF 65r), 77698 to 76799 (ORF 66r), 79343 to 77709 (ORF 67r), 79816 to 79367 (ORF 68r), 80529 to 79858 (ORF 69r), 80774 to
80529 (ORE 70r), 82815 to 80788 (ORF 71r), 83835 to 82834 (ORF 72r), 83874 to 85583 (ORF 73), 85535 to 84402 (ORF 74r), 88096 to 85574 (ORF 75r), 87759 to 88667 (ORF 76), 88920 to 88642 (ORF 77r), 91652 to 88938 (ORF 78r), 91667 to 92674 (ORF 79), 93466 to 92681 (ORF 80r), 93761 to 93486 (ORF 81r), 94060 to 93788 ,(ORF
82r), 94238 to 94080 (ORF 83r), 94508 to 94242 (ORF 84r), 95571 to 94498 (ORF 85r), 96187 to 95600 (ORF 86r), 96202 to 97665 (ORF 87), 97915 to 97643 (ORF 88r), 98251 to 99537 (ORF 89), 99537 to 99974 (ORF 90), 100001 to 101140 (ORF 91), 101168 to 104650 (ORF 92), 106354 to 104795 (ORF 93r), 107947 to 106400 (ORF 94r),
108256 to 107990 ORF 95r), 108719 to 108300 (ORF 96r), 109679 to 108738 (ORF 97r), 109861 to 109682 (ORF 98r), 110830 to 10033 (ORF 99r), 110208 to 110417 (ORF 100), 110469 to 110651 (ORF 100a), 110915 to 111397 (ORF 101), 111419 to 111913 (ORF 102), 111949 to 112485 (ORF 103), 112593 to 113450 (ORF 104), 113323 to 112967 ORF 105r), 113526 to 114152 (ORF 106), 114199 to 115236
(ORF 107), 115353 to 115787 (ORF 108), 115859 o 116551 (ORF 109), 116729 to 117523 (ORF 110), 117572 to 117114 (ORF lllr), 117423 to 118085 (ORF 12), 118968 to 118375 (ORF 114r), 118508 to 119119 (ORF 115), 119588 to 120202 (ORF 116), 120314 to 21231 (ORF 117), 121380 to 123920 (ORF 118), 121288 to 122256 (ORF
119), 122350 to 123924 (ORF 120), 123962 to 125566 (ORF 121),
125193 to 124591 (ORF 122r), 125689 to 123935 (ORF 123r), 123839 to 123297 ORF 123ar), 125652 to 126170 (ORF 124), 126121 to
. 125699 (ORF 125r), 126279 to 127769 (ORF 126), 127851 to 128408 (ORF 127), 128520 to 130076 (ORF 128), 130105 to 131700 (ORF
129), 131790 to 133283 (ORF 130), 133246 to 133920 (ORF 131), 133972 to 134370 (ORF 132), 134418 to 134693 (ORF 133a), 134402 to 134992 (ORF RI), 134853 to 134419 (ORF R2r), 135628 to 135897. (ORF R3), 136780 to 137112 ORF R4), and 137558 to 137022 (ORF R5r) ofSEQ ID 01,
alone or in combination with at least one other recombinant protein encoded by a polynucleotide selected from said group of polynucleotides, for the manufacture of a pharmaceutical composition.
8. Pharmaceutical composition comprising one or more recombinant proteins which can be expressed from polynucleotides selected from a group of polynucleotides consisting of
(a) a polynucleotide of claim 1 , (b) a polynucleotide ofclaim 2, and
(c) a polynucleotide with a sequence selected from a group of sequences consisting of nucleotides 3 to 539 (ORF LI), 781 to 449 (ORF L2r), 1933 to 1664 (ORF L3r), 3269 to 2790 (ORF L4r), 2799 to 3851 (ORF
L5), 2962 to 3753 (ORF L6), 3784 to 3122 (ORF L7r), 4341 to 4129 (ORF L8r), 4904 to 4428 (ORF lar), 6517 to 4970 (ORF lr), 8042 to 6684 (ORF 2r), 9989 to 8070 (ORF 3r), 11195 to 10062 ORF 4r), 11493 to 11227 (ORF 5r), 11802 to 12038 (ORF 6), 12358 to 12080 (ORF 7r), 13980 to 12364 (ORF 8r), 14826 to 14053 (ORF 9ar), 15080 to 15394 (ORF 10), 16838 to 15423 (ORF llr), 19021 to 16847 (ORF 12r), 19704 to 19156 (ORF 13r), 20314 to 19736 (ORF 14r), 20401 to 22101 (ORF 15), 22125 to 22940 (ORF 6), 23003 to 23866 (ORF 17), 26908 to 23873 (ORF 18r), 26926 to 27213 (ORF 19), 27626 to 27216 (ORF 20r), 29754 to 27616 (ORF 21r), 32217 to 29800 (ORF 22r),
33380 to 32418 (ORF 23r), 33602 to 33393 (ORF 24r), 34466 to 33612 (ORF 25r), 34735 to 34502 (ORF 26r), 35905 to 34739 (ORF 27r), 37194 to 35905 (ORF 28r), 37200 to 39248 (ORF 29), 41037 to 39229 (ORF 30r), 41374 to 42066 (ORF 31), 42336 to 41731 (ORF 32r), 42407 to 41997 (ORF 33r), 42410 to 43765 (ORF 34), 43770 to 43958
(ORF 35), 43980 to 44534 (ORF 36), 45727 to 44537 (ORF 37r), 45760 to 46557 (ORF 38), 46567 to 47568 (ORF 39), 47572 to 48303 (ORF 40), 48352 to 48621 (ORF 41), 49887 to 48634 (ORF 42r), 49917 to 50693 (ORF 43), 50719 to 51102 (ORF 44), 51059 to 51511 (ORF 44a), 51584 to 52591 (ORF 45), 52509 to 53066 (ORF 46), 53523 to
53023 (ORF 47r), 53607 to 57473 (ORF 48), 58070 to 57528 (ORF 49r), 57700 to 58662 (ORF 50), 59674 to 58673 (ORF 51r), 62089 to 59678 (ORF 52r), 62198 to 62881 (ORF 53), 62909 to 63862 (ORF 55), 63858 to 64271 (ORF 56), 64309 to 66831 (ORF 57), 67266 to 66799 (ORF 58r), 67803 to 67273 (ORF 58ar), 67915 to 68607 (ORF 59),
68624 to 70984 (ORF 60), 70994 to 72898 (ORF 61), 72938 to 73507 (ORF 62), 73540 to 74211 (ORF 63), 76120 to 74207 (ORF 64r), 76749 to 76186 (ORF 65r), 77698 to 76799 (ORF 66r), 79343 to 77709 (ORF 67r), 79816 to 79367 (ORF 68r), 80529 to 79858 (ORF 69r), 80774 to 80529 (ORF 70r), 82815 to 80788 (ORF 71r), 83835 to 82834 (ORF 72r), 83874 to 85583 (ORF 73), 85535 to 84402 (ORF 74r), 88096 to
85574 (ORF 75r), 87759 to 88667 (ORF 76), 88920 to 88642 (ORF 77r), 91652 to 88938 (ORF 78r), 91667 to 92674 (ORF 79), 93466 to 92681 (ORF 80r), 93761 to 93486 (ORF 81r), 94060 to 93788 (ORF 82r), 94238 to 94080 (ORF 83r), 94508 to 94242 (ORF 84r), 95571 to 94498 (ORF 85r), 96187 to 95600 (ORF 86r), 96202 to 97665 (ORF
87), 97915 to 97643 (ORF 88r), 98251 to 99537 (ORF 89), 99537 to 99974 (ORF 90), 100001 to 101140 (ORF 91), 101168 to 104650 (ORF 92), 106354 to 104795 (ORF, 93r), 107947 to 106400 (ORF 94r), 108256 to 107990 ORF 95r), 108719 to 108300 (ORF 96r), 109679 to 108738 (ORF 97r), 109861 to 109682 (ORF 98r), 110830 to 10033
(ORF 99r), 110208 to 110417 (ORF 100), 110469 to 110651 (ORF 100a), 110915 to 111397 (ORF 101), 111419 to 111913 (ORF 102), 111949 to 112485 (ORF 103), 112593 to 113450 (ORF 104), 113323 to 112967 ORF 105r), 113526 to 114152 (ORF 106), 114199 to 115236 (ORF 107), 115353 to 115787 (ORF 108), 115859 o 116551 (ORF
109), 116729 to 117523 (ORF 110), 117572 to 117114 (ORF lllr), 117423 to 118085 (ORF 12), 118968 to 118375 (ORF 114r), 118508 to 119119 (ORF 115), 119588 to 120202 (ORF 116), 120314 to 21231 (ORF 117), 121380 to 123920 (ORF 118), 121288 to 122256 (ORF 119), 122350 to 123924 (ORF 120), 123962 to 125566 (ORF 121),
125193 to 124591 (ORF 122r), 125689 to 123935 (ORF 123r), 123839 to 123297 ORF 123ar), 125652 to 126170 (ORF 124), 126121 to 125699 (ORF 125r), 126279 to 127769 (ORF 126), 127851 to 128408 (ORF 127), 128520 to 130076 (ORF 128), 130105 to 131700 (ORF 129), 131790 to 133283 (ORF 130), 133246 to 133920 (ORF 131),
133972 to 134370 (ORF 132), 134418 to 134693 (ORF 133a), 134402 to 134992 (ORF RI), 134853 to 134419 (ORF R2r), 135628 to 135897 (ORF R3), 136780 to 137112 ORF R4), and 137558 to 137022 (ORF R5r) of SEQ ID 01.
Use of recombinant proteins encoded by polynucleotides selected from a ' group of polynucleotides consisting of
(a) a polynucleotide of claim 1 ,
(b) a polynucleotide of claim 2, and
(c) a polynucleotide with a sequence selected from a group of sequences consisting of nucleotides 3 to 539 (ORF LI), 781 to 449 (ORF L2r), 1933 to 1664 (ORF L3r), 3269 to 2790 (ORF L4r), 2799 to 3851 (ORF L5), 2962 to 3753 (ORF L6), 3784 to 3122 (ORF L7r), 4341 to 4129
(ORF L8r), 4904 to 4428 (ORF lar), 6517 to 4970 (ORF Ir), 8042 to 6684 (ORF 2r), 9989 to. 8070 (ORF 3r), 11195 to 10062 ORF 4r), 11493 to 11227 (ORF 5r), 11802 to 12038 (ORF 6), 12358 to 12080 (ORF 7r), 13980 to 12364 (ORF 8r), 14826 to 14053 (ORF 9ar), 15080 to 15394 (ORF 10), 16838 to 15423 (ORF l lr), 19021 to 16847 (ORF
12r), 19704 to 19156 (ORF 13r), 20314 to 19736 (ORF 14r), 20401 to 22101 (ORF 15), 22125 to 22940 (ORF 6), 23003 to 23866 (ORF 17), 26908 to 23873 (ORF.lδr), 26926 to 27213 (ORF 19), 27626 to 27216 (ORF 20r), 29754 to 27616 (ORF 21r), 32217 to 29800 (ORF 22r), 33380 to 32418 (ORF 23r), 33602 to 33393 (ORF 24r), 34466 to 33612
(ORF 25r), 34735 to 34502 (ORF 26r), 35905 to 34739 (ORF 27r), 37194 to 35905 (ORF 28r), 37200 to 39248 (ORF 29), 41037 to 39229 (ORF 30r), 41374 to 42066 (ORF 31), 42336 to 41731 (ORF 32r), 42407 to 41997 (ORF 33r), 42410 to-43765 (ORF 34), 43770 to 43958 (ORF 35), 43980 to 44534 (ORF 36), 45727 to 44537 (ORF 37r), 45760 to 46557 (ORF 38), 46567 to 47568 (ORF 39), 47572 to 48303 (ORF 40), 48352 to 48621 (ORF 41), 49887 to 48634 (ORF 42r), 49917 to
' 50693 (ORF 43), 50719 to 51102 (ORF 44), "51059 to 51511 (ORF
44a), 51584 to 52591 (ORF 45), 52509 to 53066 (ORF 46),' 53523 to
53023 (ORF 47r), 53607 to 57473 (ORF 48), 58070 to 57528 (ORF 49r), 57700 to 58662 (ORF 50), 59674 to 58673 (ORF 51r), 62089 to
59678 (ORF 52r), 62198 to 62881 (ORF 53), 62909 to 63862 (ORF 55), 63858 to 64271 (ORF 56), 64309 to 66831 (ORF 57), 67266 to 66799 (ORF 58r), 67803 to 67273 (ORF 58ar),"67915 to 68607 (ORF 59), 68624 to 70984 (ORF 60), 70994 to 72898 (ORF 61), 72938 to 73507 (ORF 62), 73540 to 74211 (ORF 63), 76120 to 74207 (ORF 64r),- 76749 to 76186 (ORF 65r), 77698 to '76799 (ORF 66r), 79343 to 77709 (ORF 67r), 79816 to 79367 (ORF 68r), 80529 to 79858 (ORF 69r), 80774 to
80529 (ORF 70r), 82815 to 80788 (ORF 71r), 83835 to 82834 (ORF
72r), 83874 to 85583 (ORF 73), 85535 to 84402 (ORF 74r), 88096 to 85574 (ORF 75r), 87759 to 88667 (ORF 76), 88920 to 88642 (ORF
77r), 91652 to 88938 (ORF 78r), 91667 to 92674 (ORF 79), 93466 to 92681 (ORF 80r), 93761 to 93486 (ORF 81r), 94060 to 93788 (ORF 82r), 94238 to 94080 (ORF 83r), 94508 to 94242 (ORF 84r), 95571 to 94498 (ORF 85r), 96187 to 95600 (ORF 86r), 96202 to 97665 (ORE 87), 97915 to 97643 (ORF 88r), 98251 to 99537 (ORF 89), 99537 to
99974 (ORF 90), 100001 to 101140 (ORF 91), 101168 to 104650 (ORF 92), 106354 to 104795 (ORF 93r), 107947 to 106400 (ORF 94r), 108256 to 107990 ORF 95r), 108719 to 108300 (ORF 96r), 109679 to 108738 (ORF 97r), 109861 to 109682 (ORF 98r), 110830 to 10033 (ORF 99r), 110208 to 110417 (ORF 100), 110469 to 110651 (ORF
100a), 110915 to 111397 (ORF 101), 111419 to 111913 (ORF 102), 111949 to 112485 (ORF 103), 112593 to 113450 (ORF 104), 113323 to 112967 ORF 105r), 113526 to 114152 (ORF 106), 114199 to 115236 (ORF 107), 115353 to 115787 (ORF 108), 115859 o 116551 (ORF 109), 116729 to 117523 (ORF 110), 117572 to 117114 (ORF lllr),
117423 to 118085 (ORF 12), 118968 to 118375 (ORF 114r), 118508 to 119119 (ORF 115), 119588 to 120202 (ORF 116), 120314 to 21231 (ORF 117), 121380 to 123920 (ORF 118), 121288 to 122256 (ORF 119), 122350 to 123924 (ORF 120), 123962 to 125566 (ORF 121), 125193 to 124591 (ORF 122r), 125689 to 123935 (ORF 123r), 123839 to 123297 ORF 123ar), 125652 to 126170 (ORF 124), 126121 to
125699 (ORF 125r), 126279 to 127769 (ORF 126), 127851 to 128408 (ORF 127), 128520 to 130076 (ORF 128), 130105 to 131700 (ORF 129), 131790 to 133283 (ORF 130), 133246 to 133920 (ORF 131), 133972 to 134370 (ORF 132), 134418 to 134693 (ORF 133a), 134402 " to 134992 (ORF RI), 134853 to 134419 (ORF R2r), 135628 to 135897
(ORF R3), 136780 to 137112 ORF R4), and 137558 to 137022 (ORF R5r) ofSEQ ID 01,
and/or polynucleotides selected from said group of polynucleotides for the manufacture of a pharmaceutical composition for the treatment of virus related diseases, viral infections, non-viral infections, proliferative diseases, inflammatory diseases, allergic diseases, and/or autoimmune diseases.
10. Use of recombinant viruses comprising a Vaccina lister genome and fragments of a PPVO genome for the manufacture of pharmaceutial compositions.
11. Use of recombinant viruses comprising a Vaccinia lister genome and at least one heterologous gene to express at least one heterologous gene in a subject. '
12. . Use of a recombinant viruses comprising a Vaccinia lister genome and at least one heterologous gene for gene therapy.
13. A particle-like structure comprising a recombinant polypeptide encoded by an open reading frame (ORF) of the polynucleotide of SEQ ED NO: 1 or functional variants of said recombinant polypeptide.
14. Use of a particle-like structure of claim 13 for the preparation of a medicament.
15. Use of a particle-like structure of claim 13 for the preparation of a medicament for the treatment of virus related diseases, viral infections, non-viral infections, proliferative diseases, inflammatory diseases, allergic diseases, and/or autoimmune diseases.
16. A pharmaceutical composition comprising a particle-like structure of claim 13.
17. A pharmaceutical composition comprising a particle-like structure of claim 13 for the treatment of virus related diseases, viral infections, non- viral infections, proliferative diseases, inflammatory diseases, allergic diseases, and/or autoimmune diseases.
EP02808241A 2002-12-17 2002-12-17 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom Ceased EP1575614A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10178276A EP2351769A3 (en) 2002-12-17 2002-12-17 Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom
EP13175420.2A EP2647645B1 (en) 2002-12-17 2002-12-17 Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/014402 WO2004054614A1 (en) 2002-12-17 2002-12-17 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP13175420.2A Division EP2647645B1 (en) 2002-12-17 2002-12-17 Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom

Publications (1)

Publication Number Publication Date
EP1575614A1 true EP1575614A1 (en) 2005-09-21

Family

ID=32523973

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02808241A Ceased EP1575614A1 (en) 2002-12-17 2002-12-17 Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
EP13175420.2A Expired - Lifetime EP2647645B1 (en) 2002-12-17 2002-12-17 Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP13175420.2A Expired - Lifetime EP2647645B1 (en) 2002-12-17 2002-12-17 Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom

Country Status (8)

Country Link
EP (2) EP1575614A1 (en)
JP (1) JP2006515172A (en)
CN (1) CN100577205C (en)
AU (1) AU2002368464A1 (en)
CA (1) CA2510049A1 (en)
ES (1) ES2600462T3 (en)
HK (1) HK1089099A1 (en)
WO (1) WO2004054614A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375649B1 (en) * 2002-06-19 2012-03-07 Evonik Degussa GmbH D-amino acid oxidase from Arthrobacter protophormiae
EP1814575A4 (en) * 2004-11-24 2010-07-07 Neopro Labs Llc Methods and compositions for treating conditions
EP2152725A1 (en) 2007-05-17 2010-02-17 Neopro Labs, LLC Crystalline and amorphous forms of peptide
CN103079593A (en) 2010-07-20 2013-05-01 Ah美国42有限责任公司 Parapoxvirus vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049683A2 (en) * 2001-12-07 2003-06-19 Bayer Pharmacueticals Corporation Use of parapox b2l protein to treat cancer and modify immune responses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504940C2 (en) 1984-02-17 1997-11-06 Bayer Ag Multipotent paramunity mediators, processes for their preparation and medicaments containing these mediators
DE69931178T8 (en) * 1998-11-02 2007-06-28 Ludwig Institute For Cancer Research A VIRUS NZ10 ORF VIRUS NZ10 PROTEIN RELATED TO THE VASCULAR ENDOTHELIC GROWTH FACTOR BINDS AND ACTIVATES THE MAMMAL VEGF RECEPTOR-2
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049683A2 (en) * 2001-12-07 2003-06-19 Bayer Pharmacueticals Corporation Use of parapox b2l protein to treat cancer and modify immune responses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 21 May 1997 (1997-05-21), FLEMING S.B.: "Orf virus putative interleukin-10 (orfIL-10) gene, complete cds.", retrieved from NCBI Database accession no. U60552 *
FLEMING S.B. ET AL: "A Homolog of Interleukin-10 Is Encoded by the Poxvirus Orf Virus", JOURNAL OF VIROLOGY, vol. 71, no. 6, pages 4857 - 4861 *
FLEMING S.B. ET AL: "Sequence and Functional Analysis of a Homolog of Interleukin-10 encoded by the Parapoxvirus Orf Virus", VIRUS GENES, vol. 21, no. 1/2, 2000, pages 85 - 95, XP009010497 *
MERCER A.A. ET AL: "Comparative analysis of genome sequences of three isolates of Orf virus reveals unexpected sequence variation", VIRUS RESEARCH, vol. 116, 2006, pages 146 - 158, XP024957035 *
MERCER A.A. ET AL: "Location, DNA sequence and transcriptional analysis of the DNA polymerase gene of orf virus", JOURNAL OF GENERAL VIROLOGY, vol. 77, 1996, pages 1563 - 1568, XP009010495 *
See also references of WO2004054614A1 *
SULLIVAN J.T. ET AL: "Identification and Characterization of an Orf Virus Homologue of the Vaccinia Virus Gene Encoding the Major Envelope Antigen p37K", VIROLOGY, vol. 202, 1994, pages 968 - 973, XP002968954 *

Also Published As

Publication number Publication date
EP2647645A1 (en) 2013-10-09
WO2004054614A1 (en) 2004-07-01
CN1741816A (en) 2006-03-01
CN100577205C (en) 2010-01-06
HK1089099A1 (en) 2006-11-24
JP2006515172A (en) 2006-05-25
AU2002368464A1 (en) 2004-07-09
CA2510049A1 (en) 2004-07-01
ES2600462T3 (en) 2017-02-09
EP2647645B1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
US20190292231A1 (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
WO2003059381A2 (en) Immunogenic preparations and vaccines on the basis of mrna
CA2410948A1 (en) Method for the purification of alphavirus replicon particles
WO2018228538A1 (en) Recombinant herpes simplex virus, preparation method therefor, and application thereof
CN113633764B (en) New crown DNA vaccine containing adjuvant
JPH09504803A (en) Immune-inducing agent based on a combination of poxvirus components, its production method and use as a medicine
JP5037775B2 (en) Use of parapoxvirus ovis for the manufacture of antiviral drugs and medicaments against cancer
US10548946B2 (en) Therapeutic compositions for neutralizing type I interferons, and methods of use
AU2020103637A4 (en) Recombinant oncolytic herpes simplex virus type ii and its pharmaceutical composition
EP1575614A1 (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
JP5699093B2 (en) Recombinant protein of parapoxvirus Ovis and pharmaceutical composition derived therefrom
CA2840513C (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
JP5004990B2 (en) Recombinant protein of parapoxvirus Ovis and pharmaceutical composition derived therefrom
US7312202B2 (en) Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy
EP2351769A2 (en) Recombinant proteins of Parapoxvirus ovis and pharmaceutical compositions therefrom
WO2021239586A1 (en) Adenovirus for anti-tumour therapy
JP2002544236A (en) Organ, tissue and cell-specific immunotherapeutic agents for hepatic chronic viral infections and inflammatory, degenerative and proliferative diseases and cancer, especially based on recombinant parapoxvirus
KR20120013260A (en) Vaccines for Cervical Cancer
WO2023016572A1 (en) Modified vaccinia virus and application thereof
JP7483853B2 (en) Anti-infective effect of hnRNPA2B1 and its applications
WO2024085723A1 (en) Ferritin protein structure displaying sars-cov-2 s1-derived protein and antibody fc region protein simultaneously on surface, and use thereof for vaccine for coronavirus sars-cov-2
KR100805996B1 (en) Use of Strains of the Parapox Ovis Virus for Producing Antiviral Pharmaceuticals and Anticancer Pharmaceuticals
JP2020529391A5 (en)
KR20040006196A (en) Composition of genetic adjuvants comprising cationic polymer
WO2004096852A1 (en) A RECOMBINANT HUMAN INTERFERON ϖ, THE METHOD FOR EXPRESSING IT AND THE USES OF IT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): CH DE ES FR IT LI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VOLK, HANS-DIETER

Inventor name: FLEMING, STEPHEN BRUCE

Inventor name: MERCER, ANDREW ALLAN

Inventor name: SCHLAPP, TOBIAS

Inventor name: SIEGLING, ANGELA

Inventor name: FRIEDERICHS, SONJA MARIA

Inventor name: WEBER, OLAF,C/O BAYER CORP.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VOLK, HANS-DIETER

Inventor name: FLEMING, STEPHEN BRUCE

Inventor name: MERCER, ANDREW ALLAN

Inventor name: SCHLAPP, TOBIAS

Inventor name: SIEGLING, ANGELA

Inventor name: FRIEDERICHS, SONJA MARIA

Inventor name: WEBER, OLAF,C/O BAYER CORP.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AICURIS GMBH & CO. KG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AICURIS GMBH & CO. KG

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160429